Arvinas, Inc. (ARVN) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to our Venus third quarter 2025 earnings call. I'd like to remind everyone that this call is being recorded and that all lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Mr. Jeff Boyle. You may begin. Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release with our third quarter 2025 financial results, which is available in the investor and media section of our website at arvinas.com. Joining the call today are John Huston, Arvinas' chief executive officer, president, and chairperson, Noah Berkowitz, our chief medical officer, Angela Cacasey, our chief scientific officer, and Andrew Sake, our Chief Financial Officer. Before we begin the call, I'll remind you that today's discussions contain forward-looking statements that involve risks, uncertainties, and assumptions, which are outlined in today's press release and in the company's recent filings with the U.S. Securities and Exchange Commission, which I urge you to read. Our actual results may differ materially from what is discussed on today's call. A replay of today's call, as well as an updated corporate deck, will be available in the Investor and Media section of our website. And now I'll turn the call over to John. John? Thanks, Jeff. Good morning, everyone, and thank you for joining us today. As highlighted in our third quarter earnings release issued earlier this morning, this has been a dynamic and product...